About: Bernard Escudier

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Bernard Escudier Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) ikertzailea (eu) researcher (en) 연구원 (ko) ricercatore (it) 研究者 (ja) дослідник (uk) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) onderzoeker (nl)
rdfs:label	Bernard Escudier (en) Bernard Escudier (es) Bernard Escudier (fr) Bernard Escudier (nl) Bernard Escudier (sl) Bernard Escudier (ast)
skos:prefLabel	Bernard Escudier (en) Bernard Escudier (es) Bernard Escudier (fr) Bernard Escudier (nl) Bernard Escudier (sl) Bernard Escudier (ast)
name	Bernard Escudier (en) Bernard Escudier (es) Bernard Escudier (fr) Bernard Escudier (nl) Bernard Escudier (sl) Bernard Escudier (ast)
given name	wds:Q54553923-AD2BC6D2-65BB-477A-8573-E23512FE3AA7
given name	Bernard
instance of	wds:Q54553923-E1CA4F4D-0F39-496C-A66E-129EA16AD493
instance of	Homo sapiens
occupation	wds:Q54553923-C2FEB414-42F5-4045-A199-77A556CBFFDD
NUKAT ID	wds:Q54553923-149B28AA-594A-493B-8139-93134913F78D
sex or gender	wds:Q54553923-E5FC6135-C2AB-442E-9BD1-3E269016C34F
ISNI	wds:Q54553923-B8ED70F7-91FB-4515-9227-8B423DBB4235
VIAF ID	wds:Q54553923-0BECBECF-4BAF-4362-9137-B1B1BBE430F4
Bibliothèque nationale de France ID	wds:Q54553923-53B57C0C-D350-41C5-A7B2-BEDDB7A18C38
IdRef ID	wds:Q54553923-2C8EEE12-2459-4A44-A626-97069EBCB25C
date of birth	wds:Q54553923-be2d884d-48a6-a3aa-34e8-c4a807872634
family name	wds:Q54553923-338FE238-BFB1-4ADD-94CF-8884A90023A3
WorldCat Identities ID (superseded)	wds:Q54553923-AD7D1536-6A3A-48ED-A42D-BD6CE332D06E
National Library of Spain ID	wds:Q54553923-EDCB80C5-2812-4A3C-83A2-CEB540DE7F7E
VIAF ID	http://viaf.org/viaf/140713428
Bibliothèque nationale de France ID	http://data.bnf.fr/ark:/12148/cb13053178j#about
IdRef ID	http://www.idref.fr/144480921/id
National Library of Spain ID	http://datos.bne.es/resource/XX5392600
occupation	researcher
NUKAT ID	n2017007509
sex or gender	male
ISNI	0000000095414505
VIAF ID	140713428
Bibliothèque nationale de France ID	13053178j
IdRef ID	144480921
date of birth	1952-01-01 00:00:00Z (xsd:dateTime)
family name	Escudier
WorldCat Identities ID (superseded)	viaf-140713428
National Library of Spain ID	XX5392600
ORCID iD	wds:Q54553923-E95EBAA0-6194-4CED-85EC-97137255A189
ORCID iD	https://orcid.org/0000-0002-4626-0479
ORCID iD	0000-0002-4626-0479
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q54553923
is author of	Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma Cutaneous side-effects of kinase inhibitors and blocking antibodies Experience with sorafenib and the elderly patient Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial Sequential therapy in renal cell carcinoma Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors Radiotherapy for renal-cell carcinoma Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma Malignant effusions and immunogenic tumour-derived exosomes Targeted therapies for renal cell carcinoma: review of adverse event management strategies

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software